Recombinant Proteins Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)

Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segments

1.4.1. Market size breakdown, by end user

1.4.2. Market size breakdown, by application

1.4.3. Market size breakdown, by product

1.4.4. Market size breakdown, by region

1.4.5. Market size breakdown, by country

1.5. Market Data Reporting Unit

1.5.1. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Industry Outlook

6.1. Market Dynamics

6.1.1. Trends

6.1.2. Drivers

6.1.3. Restraints/challenges

6.1.4. Impact analysis of drivers/restraints

6.2. Impact of COVID-19

6.3. Porter’s Five Forces Analysis

6.3.1. Bargaining power of buyers

6.3.2. Bargaining power of suppliers

6.3.3. Threat of new entrants

6.3.4. Intensity of rivalry

6.3.5. Threat of substitutes

Chapter 7. Global Market

7.1. Overview

7.2. Market Revenue, by End User (2019–2030)

7.3. Market Revenue, by Application (2019–2030)

7.3.1. Drug discovery & development market revenue, by application (2019–2030)

7.4. Market Revenue, by Product (2019–2030)

7.5. Market Revenue, by Region (2019–2030)

Chapter 8. North America Market

8.1. Overview

8.2. Market Revenue, by End User (2019–2030)

8.3. Market Revenue, by Application (2019–2030)

8.3.1. Drug discovery & development market revenue, by application (2019–2030)

8.4. Market Revenue, by Product (2019–2030)

8.5. Market Revenue, by Country (2019–2030)

Chapter 9. Europe Market

9.1. Overview

9.2. Market Revenue, by End User (2019–2030)

9.3. Market Revenue, by Application (2019–2030)

9.3.1. Drug discovery & development market revenue, by application (2019–2030)

9.4. Market Revenue, by Product (2019–2030)

9.5. Market Revenue, by Country (2019–2030)

Chapter 10. APAC Market

10.1. Overview

10.2. Market Revenue, by End User (2019–2030)

10.3. Market Revenue, by Application (2019–2030)

10.3.1. Drug discovery & development market revenue, by application (2019–2030)

10.4. Market Revenue, by Product (2019–2030)

10.5. Market Revenue, by Country (2019–2030)

Chapter 11. LATAM Market

11.1. Overview

11.2. Market Revenue, by End User (2019–2030)

11.3. Market Revenue, by Application (2019–2030)

11.3.1. Drug discovery & development market revenue, by application (2019–2030)

11.4. Market Revenue, by Product (2019–2030)

11.5. Market Revenue, by Country (2019–2030)

Chapter 12. MEA Market

12.1. Overview

12.2. Market Revenue, by End User (2019–2030)

12.3. Market Revenue, by Application (2019–2030)

12.3.1. Drug discovery & development market revenue, by application (2019–2030)

12.4. Market Revenue, by Product (2019–2030)

12.5. Market Revenue, by Country (2019–2030)

Chapter 13. U.S. Market

13.1. Overview

13.2. Market Revenue, by End User (2019–2030)

13.3. Market Revenue, by Application (2019–2030)

13.3.1. Drug discovery & development market revenue, by application (2019–2030)

13.4. Market Revenue, by Product (2019–2030)

Chapter 14. Canada Market

14.1. Overview

14.2. Market Revenue, by End User (2019–2030)

14.3. Market Revenue, by Application (2019–2030)

14.3.1. Drug discovery & development market revenue, by application (2019–2030)

14.4. Market Revenue, by Product (2019–2030)

Chapter 15. Germany Market

15.1. Overview

15.2. Market Revenue, by End User (2019–2030)

15.3. Market Revenue, by Application (2019–2030)

15.3.1. Drug discovery & development market revenue, by application (2019–2030)

15.4. Market Revenue, by Product (2019–2030)

Chapter 16. France Market

16.1. Overview

16.2. Market Revenue, by End User (2019–2030)

16.3. Market Revenue, by Application (2019–2030)

16.3.1. Drug discovery & development market revenue, by application (2019–2030)

16.4. Market Revenue, by Product (2019–2030)

Chapter 17. U.K. Market

17.1. Overview

17.2. Market Revenue, by End User (2019–2030)

17.3. Market Revenue, by Application (2019–2030)

17.3.1. Drug discovery & development market revenue, by application (2019–2030)

17.4. Market Revenue, by Product (2019–2030)

Chapter 18. Italy Market

18.1. Overview

18.2. Market Revenue, by End User (2019–2030)

18.3. Market Revenue, by Application (2019–2030)

18.3.1. Drug discovery & development market revenue, by application (2019–2030)

18.4. Market Revenue, by Product (2019–2030)

Chapter 19. Spain Market

19.1. Overview

19.2. Market Revenue, by End User (2019–2030)

19.3. Market Revenue, by Application (2019–2030)

19.3.1. Drug discovery & development market revenue, by application (2019–2030)

19.4. Market Revenue, by Product (2019–2030)

Chapter 20. Japan Market

20.1. Overview

20.2. Market Revenue, by End User (2019–2030)

20.3. Market Revenue, by Application (2019–2030)

20.3.1. Drug discovery & development market revenue, by application (2019–2030)

20.4. Market Revenue, by Product (2019–2030)

Chapter 21. China Market

21.1. Overview

21.2. Market Revenue, by End User (2019–2030)

21.3. Market Revenue, by Application (2019–2030)

21.3.1. Drug discovery & development market revenue, by application (2019–2030)

21.4. Market Revenue, by Product (2019–2030)

Chapter 22. India Market

22.1. Overview

22.2. Market Revenue, by End User (2019–2030)

22.3. Market Revenue, by Application (2019–2030)

22.3.1. Drug discovery & development market revenue, by application (2019–2030)

22.4. Market Revenue, by Product (2019–2030)

Chapter 23. Australia Market

23.1. Overview

23.2. Market Revenue, by End User (2019–2030)

23.3. Market Revenue, by Application (2019–2030)

23.3.1. Drug discovery & development market revenue, by application (2019–2030)

23.4. Market Revenue, by Product (2019–2030)

Chapter 24. South Korea Market

24.1. Overview

24.2. Market Revenue, by End User (2019–2030)

24.3. Market Revenue, by Application (2019–2030)

24.3.1. Drug discovery & development market revenue, by application (2019–2030)

24.4. Market Revenue, by Product (2019–2030)

Chapter 25. Brazil Market

25.1. Overview

25.2. Market Revenue, by End User (2019–2030)

25.3. Market Revenue, by Application (2019–2030)

25.3.1. Drug discovery & development market revenue, by application (2019–2030)

25.4. Market Revenue, by Product (2019–2030)

Chapter 26. Mexico Market

26.1. Overview

26.2. Market Revenue, by End User (2019–2030)

26.3. Market Revenue, by Application (2019–2030)

26.3.1. Drug discovery & development market revenue, by application (2019–2030)

26.4. Market Revenue, by Product (2019–2030)

Chapter 27. Saudi Arabia Market

27.1. Overview

27.2. Market Revenue, by End User (2019–2030)

27.3. Market Revenue, by Application (2019–2030)

27.3.1. Drug discovery & development market revenue, by application (2019–2030)

27.4. Market Revenue, by Product (2019–2030)

Chapter 28. South Africa Market

28.1. Overview

28.2. Market Revenue, by End User (2019–2030)

28.3. Market Revenue, by Application (2019–2030)

28.3.1. Drug discovery & development market revenue, by application (2019–2030)

28.4. Market Revenue, by Product (2019–2030)

Chapter 29. U.A.E. Market

29.1. Overview

29.2. Market Revenue, by End User (2019–2030)

29.3. Market Revenue, by Application (2019–2030)

29.3.1. Drug discovery & development market revenue, by application (2019–2030)

29.4. Market Revenue, by Product (2019–2030)

Chapter 30. Competitive Landscape

30.1. List of Market Players and their Offerings

30.2. Competitive Benchmarking of Key Players

30.3. Product Benchmarking of Key Players

30.4. Recent Strategic Developments

Chapter 31. Company Profiles

31.1. Thermo Fisher Scientific Inc.

31.1.1. Business overview

31.1.2. Product and service offerings

31.1.3. Key financial summary

31.2. Merck KGaA

31.2.1. Business overview

31.2.2. Product and service offerings

31.2.3. Key financial summary

31.3. Abcam plc

31.3.1. Business overview

31.3.2. Product and service offerings

31.3.3. Key financial summary

31.4. Bio-Rad Laboratories Inc.

31.4.1. Business overview

31.4.2. Product and service offerings

31.4.3. Key financial summary

31.5. Bio-Techne Corporation

31.5.1. Business overview

31.5.2. Product and service offerings

31.5.3. Key financial summary

31.6. Miltenyi Biotec B.V. & Co. KG

31.6.1. Business overview

31.6.2. Product and service offerings

31.7. ACROBiosystems

31.7.1. Business overview

31.7.2. Product and service offerings

31.8. RayBiotech Life Inc.

31.8.1. Business overview

31.8.2. Product and service offerings

31.9. Aviva Systems Biology Corporation

31.9.1. Business overview

31.9.2. Product and service offerings

31.10. Enzo Biochem Inc.

31.10.1. Business overview

31.10.2. Product and service offerings

31.10.3. Key financial summary

31.11. Sino Biological Inc.

31.11.1. Business overview

31.11.2. Product and service offerings

31.11.3. Key financial summary

31.12. BioLegend Inc.

31.12.1. Business overview

31.12.2. Product and service offerings

31.13. Synbio Technologies

31.13.1. Business overview

31.13.2. Product and service offerings

31.14. United States Biological

31.14.1. Business overview

31.14.2. Product and service offerings

31.15. StemCell Technologies Inc.

31.15.1. Business overview

31.15.2. Product and service offerings

Chapter 32. Appendix

32.1. Abbreviations

32.2. Sources and References

32.3. Related Reports

 

LIST OF TABLES

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 5 GLOBAL RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 6 GLOBAL RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 7 GLOBAL RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 8 GLOBAL RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 9 GLOBAL RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 10 GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 11 GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 12 GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 13 GLOBAL RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 14 GLOBAL RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 15 GLOBAL RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 16 GLOBAL RECOMBINANT PROTEINS MARKET, BY REGION, $M (2017–2022)

TABLE 17 GLOBAL RECOMBINANT PROTEINS MARKET, BY REGION, $M (2023–2026)

TABLE 18 GLOBAL RECOMBINANT PROTEINS MARKET, BY REGION, $M (2027–2030)

TABLE 19 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 20 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 21 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 22 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 23 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 24 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 25 NORTH AMERICA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 26 NORTH AMERICA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 27 NORTH AMERICA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 28 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 29 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 30 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 31 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 32 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2023–2026)

TABLE 33 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2027–2030)

TABLE 34 EUROPE RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 35 EUROPE RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 36 EUROPE RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 37 EUROPE RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 38 EUROPE RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 39 EUROPE RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 40 EUROPE DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 41 EUROPE DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 42 EUROPE DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 43 EUROPE RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 44 EUROPE RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 45 EUROPE RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 46 EUROPE RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 47 EUROPE RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2023–2026)

TABLE 48 EUROPE RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2027–2030)

TABLE 49 APAC RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 50 APAC RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 51 APAC RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 52 APAC RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 53 APAC RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 54 APAC RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 55 APAC DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 56 APAC DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 57 APAC DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 58 APAC RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 59 APAC RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 60 APAC RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 61 APAC RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 62 APAC RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2023–2026)

TABLE 63 APAC RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2027–2030)

TABLE 64 LATAM RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 65 LATAM RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 66 LATAM RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 67 LATAM RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 68 LATAM RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 69 LATAM RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 70 LATAM DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 71 LATAM DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 72 LATAM DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 73 LATAM RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 74 LATAM RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 75 LATAM RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 76 LATAM RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 77 LATAM RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2023–2026)

TABLE 78 LATAM RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2027–2030)

TABLE 79 MEA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 80 MEA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 81 MEA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 82 MEA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 83 MEA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 84 MEA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 85 MEA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 86 MEA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 87 MEA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 88 MEA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 89 MEA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 90 MEA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 91 MEA RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 92 MEA RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2023–2026)

TABLE 93 MEA RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2027–2030)

TABLE 94 U.S. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 95 U.S. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 96 U.S. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 97 U.S. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 98 U.S. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 99 U.S. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 100 U.S. DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 101 U.S. DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 102 U.S. DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 103 U.S. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 104 U.S. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 105 U.S. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 106 CANADA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 107 CANADA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 108 CANADA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 109 CANADA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 110 CANADA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 111 CANADA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 112 CANADA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 113 CANADA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 114 CANADA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 115 CANADA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 116 CANADA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 117 CANADA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 118 GERMANY RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 119 GERMANY RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 120 GERMANY RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 121 GERMANY RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 122 GERMANY RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 123 GERMANY RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 124 GERMANY DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 125 GERMANY DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 126 GERMANY DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 127 GERMANY RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 128 GERMANY RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 129 GERMANY RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 130 FRANCE RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 131 FRANCE RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 132 FRANCE RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 133 FRANCE RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 134 FRANCE RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 135 FRANCE RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 136 FRANCE DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 137 FRANCE DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 138 FRANCE DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 139 FRANCE RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 140 FRANCE RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 141 FRANCE RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 142 U.K. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 143 U.K. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 144 U.K. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 145 U.K. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 146 U.K. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 147 U.K. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 148 U.K. DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 149 U.K. DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 150 U.K. DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 151 U.K. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 152 U.K. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 153 U.K. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 154 ITALY RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 155 ITALY RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 156 ITALY RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 157 ITALY RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 158 ITALY RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 159 ITALY RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 160 ITALY DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 161 ITALY DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 162 ITALY DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 163 ITALY RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 164 ITALY RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 165 ITALY RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 166 SPAIN RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 167 SPAIN RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 168 SPAIN RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 169 SPAIN RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 170 SPAIN RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 171 SPAIN RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 172 SPAIN DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 173 SPAIN DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 174 SPAIN DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 175 SPAIN RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 176 SPAIN RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 177 SPAIN RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 178 JAPAN RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 179 JAPAN RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 180 JAPAN RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 181 JAPAN RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 182 JAPAN RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 183 JAPAN RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 184 JAPAN DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 185 JAPAN DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 186 JAPAN DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 187 JAPAN RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 188 JAPAN RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 189 JAPAN RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 190 CHINA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 191 CHINA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 192 CHINA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 193 CHINA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 194 CHINA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 195 CHINA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 196 CHINA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 197 CHINA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 198 CHINA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 199 CHINA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 200 CHINA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 201 CHINA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 202 INDIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 203 INDIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 204 INDIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 205 INDIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 206 INDIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 207 INDIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 208 INDIA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 209 INDIA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 210 INDIA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 211 INDIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 212 INDIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 213 INDIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 214 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 215 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 216 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 217 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 218 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 219 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 220 AUSTRALIA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 221 AUSTRALIA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 222 AUSTRALIA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 223 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 224 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 225 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 226 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 227 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 228 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 229 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 230 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 231 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 232 SOUTH KOREA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 233 SOUTH KOREA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 234 SOUTH KOREA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 235 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 236 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 237 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 238 BRAZIL RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 239 BRAZIL RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 240 BRAZIL RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 241 BRAZIL RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 242 BRAZIL RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 243 BRAZIL RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 244 BRAZIL DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 245 BRAZIL DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 246 BRAZIL DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 247 BRAZIL RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 248 BRAZIL RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 249 BRAZIL RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 250 MEXICO RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 251 MEXICO RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 252 MEXICO RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 253 MEXICO RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 254 MEXICO RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 255 MEXICO RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 256 MEXICO DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 257 MEXICO DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 258 MEXICO DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 259 MEXICO RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 260 MEXICO RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 261 MEXICO RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 262 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 263 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 264 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 265 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 266 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 267 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 268 SAUDI ARABIA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 269 SAUDI ARABIA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 270 SAUDI ARABIA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 271 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 272 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 273 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 274 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 275 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 276 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 277 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 278 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 279 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 280 SOUTH AFRICA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 281 SOUTH AFRICA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 282 SOUTH AFRICA DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 283 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 284 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 285 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 286 U.A.E. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2017–2022)

TABLE 287 U.A.E. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2023–2026)

TABLE 288 U.A.E. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2027–2030)

TABLE 289 U.A.E. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2017–2022)

TABLE 290 U.A.E. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2023–2026)

TABLE 291 U.A.E. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2027–2030)

TABLE 292 U.A.E. DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2017–2022)

TABLE 293 U.A.E. DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2023–2026)

TABLE 294 U.A.E. DRUG DISCOVERY & DEVELOPMENT MARKET, BY APPLICATION, $M (2027–2030)

TABLE 295 U.A.E. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2017–2022)

TABLE 296 U.A.E. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2023–2026)

TABLE 297 U.A.E. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2027–2030)

TABLE 298 THERMO FISHER SCIENTIFIC INC. – AT A GLANCE

TABLE 299 THERMO FISHER SCIENTIFIC INC. – KEY FINANCIAL SUMMARY

TABLE 300 MERCK KGAA – AT A GLANCE

TABLE 301 MERCK KGAA – KEY FINANCIAL SUMMARY

TABLE 302 ABCAM PLC – AT A GLANCE

TABLE 303 ABCAM PLC – KEY FINANCIAL SUMMARY

TABLE 304 BIO-RAD LABORATORIES INC. – AT A GLANCE

TABLE 305 BIO-RAD LABORATORIES INC. – KEY FINANCIAL SUMMARY

TABLE 306 BIO-TECHNE CORPORATION – AT A GLANCE

TABLE 307 BIO-TECHNE CORPORATION – KEY FINANCIAL SUMMARY

TABLE 308 MILTENYI BIOTEC B.V. & CO. KG – AT A GLANCE

TABLE 309 ACROBIOSYSTEMS – AT A GLANCE

TABLE 310 RAYBIOTECH LIFE INC. – AT A GLANCE

TABLE 311 AVIVA SYSTEMS BIOLOGY CORPORATION – AT A GLANCE

TABLE 312 ENZO BIOCHEM INC. – AT A GLANCE

TABLE 313 ENZO BIOCHEM INC. – KEY FINANCIAL SUMMARY

TABLE 314 SINO BIOLOGICAL INC. – AT A GLANCE

TABLE 315 SINO BIOLOGICAL INC. – KEY FINANCIAL SUMMARY

TABLE 316 BIOLEGEND INC. – AT A GLANCE

TABLE 317 SYNBIO TECHNOLOGIES – AT A GLANCE

TABLE 318 UNITED STATES BIOLOGICAL – AT A GLANCE

TABLE 319 STEMCELL TECHNOLOGIES INC. – AT A GLANCE

 

LIST OF FIGURES

FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT

FIG 2 RESEARCH METHODOLOGY

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 6 DATA TRIANGULATION APPROACH

FIG 7 CURRENCY CONVERSION RATES FOR USD (2023)

FIG 8 GLOBAL RECOMBINANT PROTEINS MARKET SUMMARY

FIG 9 BARGAINING POWER OF BUYERS

FIG 10 BARGAINING POWER OF SUPPLIERS

FIG 11 THREAT OF NEW ENTRANTS

FIG 12 INTENSITY OF RIVALRY

FIG 13 THREAT OF SUBSTITUTES

FIG 14 GLOBAL RECOMBINANT PROTEINS MARKET SNAPSHOT

FIG 15 GLOBAL RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 16 GLOBAL RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 17 GLOBAL RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 18 MAJOR WORLDWIDE MARKETS FOR RECOMBINANT PROTEINS, $M

FIG 19 NORTH AMERICA RECOMBINANT PROTEINS MARKET SNAPSHOT

FIG 20 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 21 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 22 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 23 NORTH AMERICA RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2019–2030)

FIG 24 EUROPE RECOMBINANT PROTEINS MARKET SNAPSHOT

FIG 25 EUROPE RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 26 EUROPE RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 27 EUROPE RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 28 EUROPE RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2019–2030)

FIG 29 APAC RECOMBINANT PROTEINS MARKET SNAPSHOT

FIG 30 APAC RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 31 APAC RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 32 APAC RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 33 APAC RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2019–2030)

FIG 34 LATAM RECOMBINANT PROTEINS MARKET SNAPSHOT

FIG 35 LATAM RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 36 LATAM RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 37 LATAM RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 38 LATAM RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2019–2030)

FIG 39 MEA RECOMBINANT PROTEINS MARKET SNAPSHOT

FIG 40 MEA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 41 MEA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 42 MEA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 43 MEA RECOMBINANT PROTEINS MARKET, BY COUNTRY, $M (2019–2030)

FIG 44 U.S. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 45 U.S. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 46 U.S. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 47 CANADA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 48 CANADA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 49 CANADA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 50 GERMANY RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 51 GERMANY RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 52 GERMANY RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 53 FRANCE RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 54 FRANCE RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 55 FRANCE RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 56 U.K. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 57 U.K. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 58 U.K. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 59 ITALY RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 60 ITALY RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 61 ITALY RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 62 SPAIN RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 63 SPAIN RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 64 SPAIN RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 65 JAPAN RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 66 JAPAN RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 67 JAPAN RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 68 CHINA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 69 CHINA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 70 CHINA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 71 INDIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 72 INDIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 73 INDIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 74 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 75 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 76 AUSTRALIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 77 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 78 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 79 SOUTH KOREA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 80 BRAZIL RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 81 BRAZIL RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 82 BRAZIL RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 83 MEXICO RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 84 MEXICO RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 85 MEXICO RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 86 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 87 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 88 SAUDI ARABIA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 89 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 90 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 91 SOUTH AFRICA RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 92 U.A.E. RECOMBINANT PROTEINS MARKET, BY END USER, $M (2019–2030)

FIG 93 U.A.E. RECOMBINANT PROTEINS MARKET, BY APPLICATION, $M (2019–2030)

FIG 94 U.A.E. RECOMBINANT PROTEINS MARKET, BY PRODUCT, $M (2019–2030)

FIG 95 THERMO FISHER SCIENTIFIC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 96 MERCK KGAA – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 97 ABCAM PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 98 BIO-RAD LABORATORIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 99 BIO-TECHNE CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 100 ENZO BIOCHEM INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 101 SINO BIOLOGICAL INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)